Abstract
2′ Deoxycoformycin is a new chemotherapeutic agent with promising application in lymphoblastic leukemias. Previous Phase I trials have not indicated potential for pulmonary toxicity. We wish to report a case of respiratory failure presenting with sudden onset of severe hypoxia, tachypnea, and rapid evolution of diffuse alveolar infiltrates and pleural effusions. Aggressive management with high level positive end-expiratory pressure (PEEP) and steroids achieved a successful outcome.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Smyth JF, Young R, Young DM (1978) In vivo toxicity to lympoid tissue by 2′ Deoxycoformycin. Cancer Chemother Pharmacol 1:49
Smyth JF, Chassin NM, Harrup KR, Adamson RH, Johns DG (1979) 2′ Deoxycoformycin: Phase I trial and clinical pharmacology. Proc AACR ASCO 20:47 (Abstract)
O'Brien TG, Sweeney DF (1973) Interstitial viral pneumonitis complicated by severe respiratory failure. Successful management using intensive dehydration and steroids. Chest 63:314
Fein A, Grossman RF, Jones JG, et al (1979) The value of edema fluid protein measurement in patients with pulmonary edema. Am J Med 67:32
Rosenow EC III (1972) The spectrum of drug-induced pulmonary disease. Ann Intern Med 77:977
Author information
Authors and Affiliations
Additional information
Supported by grants from the National Cancer Institution, Ca 08748 and Ca 05826
Rights and permissions
About this article
Cite this article
Kahn, R.C., Carlon, G.C., Miller, L. et al. Acute respiratory failure due to 2′ deoxycoformycin. Intensive Care Med 8, 101–104 (1982). https://doi.org/10.1007/BF01694876
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01694876